Hims & Hers Health (NYSE:HIMS) Announces Quarterly Earnings Results

Hims & Hers Health (NYSE:HIMS) announced its earnings results on Monday. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26, Briefing.com reports. The business had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business’s revenue was up 77.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.04) earnings per share. Hims & Hers Health updated its Q4 2024 guidance to EPS and its FY 2024 guidance to EPS.

Hims & Hers Health Trading Up 0.5 %

NYSE HIMS traded up $0.11 during trading hours on Tuesday, reaching $20.87. The company had a trading volume of 34,408,063 shares, compared to its average volume of 8,451,947. Hims & Hers Health has a 1-year low of $6.23 and a 1-year high of $25.74. The stock has a market capitalization of $4.48 billion, a P/E ratio of 271.03 and a beta of 1.06. The stock has a 50-day moving average of $18.10 and a 200 day moving average of $18.19.

Insider Activity

In related news, insider Soleil Boughton sold 2,345 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.65, for a total value of $34,354.25. Following the completion of the sale, the insider now owns 159,796 shares in the company, valued at approximately $2,341,011.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Hims & Hers Health news, insider Soleil Boughton sold 2,345 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $14.65, for a total transaction of $34,354.25. Following the sale, the insider now directly owns 159,796 shares in the company, valued at $2,341,011.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 11,609 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.60, for a total transaction of $169,491.40. Following the completion of the transaction, the chief financial officer now directly owns 181,469 shares of the company’s stock, valued at approximately $2,649,447.40. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 650,659 shares of company stock valued at $11,712,198. Company insiders own 17.71% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the company. Deutsche Bank Aktiengesellschaft increased their price objective on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. Truist Financial raised their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. TD Cowen upped their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Finally, Needham & Company LLC started coverage on Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price on the stock. Eight research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $20.71.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.